Want to see DE:SRT3 full AI Analyst Report?
Top Page
Sartorius
(XETRA:SRT3)
Select Model
Select Model
Rating:48Neutral
Price Target:
€220.00
▼(-0.45% Downside)
Action:Reiterated
Date:07/24/26
The score is held back mainly by leveraged and mixed financial quality (low/volatile net margins, elevated debt-to-equity, uneven cash conversion) and weak technicals (below major moving averages with slightly negative momentum). Strong recent revenue growth and solid operating margins help, but the very high P/E with a low dividend yield provides little valuation support.
Positive Factors
Revenue Growth
A sustained +77% TTM revenue acceleration indicates durable demand for Sartorius’ products and expanding market penetration. Strong top-line growth supports scale advantages, expands the installed base that drives recurring consumables and services, and underpins longer-term organic expansion.
Negative Factors
Elevated Leverage
High leverage (~1.6x D/E) limits financial flexibility and raises refinancing and interest-rate exposure over time. Elevated debt constrains capacity for large inorganic investments or aggressive buybacks, and increases downside risk if revenue or margins weaken, reducing resilience over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A sustained +77% TTM revenue acceleration indicates durable demand for Sartorius’ products and expanding market penetration. Strong top-line growth supports scale advantages, expands the installed base that drives recurring consumables and services, and underpins longer-term organic expansion.
Read all positive factors
Sartorius (SRT3) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€13.65B
Dividend Yield0.34%
Average Volume (3M)153.86K
Price to Earnings (P/E)77.0
Beta (1Y)1.32
Revenue Growth3.29%
EPS Growth88.34%
CountryDE
Employees14,279
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.83
Shares Outstanding37,440,000
10 Day Avg. Volume126,110
30 Day Avg. Volume153,863
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€255.88Price Target Upside15.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)5.28
Revenue Forecast (FY)€3.73B
Sartorius Business Overview & Revenue Model
Company Description
Sartorius AG is a global supplier of advanced bioprocess and laboratory solutions, offering a comprehensive portfolio of products and services essential for life science research and biopharmaceutical manufacturing. The company's offerings include...
How the Company Makes Money
Sartorius makes money by selling products and services that are embedded in customers’ laboratory workflows and biomanufacturing processes, generating revenue from both recurring consumables and higher-value equipment and systems.
Key revenue str...
Sartorius Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
44
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.58B | 3.54B | 3.38B | 3.40B | 4.17B | 3.45B |
| Gross Profit | 1.64B | 1.64B | 1.52B | 1.57B | 2.20B | 1.84B |
| EBITDA | 1.04B | 1.07B | 786.80M | 873.10M | 1.50B | 945.12M |
| Net Income | 171.40M | 154.90M | 84.00M | 205.20M | 913.10M | 426.98M |
Balance Sheet | ||||||
| Total Assets | 9.60B | 9.72B | 10.10B | 9.76B | 6.98B | 5.70B |
| Cash, Cash Equivalents and Short-Term Investments | 306.90M | 551.80M | 828.70M | 394.20M | 196.80M | 360.99M |
| Total Debt | 4.05B | 4.28B | 4.56B | 5.31B | 2.54B | 2.08B |
| Total Liabilities | 5.60B | 5.85B | 6.21B | 7.00B | 4.32B | 3.98B |
| Stockholders Equity | 2.82B | 2.71B | 2.76B | 2.07B | 1.99B | 1.26B |
Cash Flow | ||||||
| Free Cash Flow | 292.90M | 214.10M | 566.30M | 293.90M | 211.60M | 458.65M |
| Operating Cash Flow | 734.40M | 656.00M | 976.20M | 853.60M | 734.20M | 865.81M |
| Investing Cash Flow | -504.70M | -513.50M | -425.80M | -2.82B | -1.13B | -569.61M |
| Financing Cash Flow | -760.50M | -410.60M | -128.30M | 2.17B | 209.90M | -165.18M |
Sartorius Technical Analysis
Neutral
221.00
Price Trends
230.88
Negative
224.69
Positive
232.06
Negative
Market Momentum
-2.66
Positive
48.21
Neutral
44.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT3, the sentiment is Neutral. The current price of 221 is below the 20-day moving average (MA) of 230.57, below the 50-day MA of 230.88, and below the 200-day MA of 232.06, indicating a bearish trend. The MACD of -2.66 indicates Positive momentum. The RSI at 48.21 is Neutral, neither overbought nor oversold. The STOCH value of 44.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:SRT3.
Sartorius Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | €2.73B | 22.43 | 4.27% | 1.98% | -0.06% | -38.81% | |
66 Neutral | €9.96B | 23.99 | 17.42% | 2.05% | 1.30% | 10.05% | |
59 Neutral | €1.62B | 26.68 | 11.05% | 4.66% | -3.90% | 60.48% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | €951.23M | -2.97 | -23.57% | 0.15% | 14.00% | -391.94% | |
49 Neutral | €237.28M | -72.30 | -1.37% | 3.05% | ― | ― | |
48 Neutral | €13.65B | 77.03 | 6.28% | 0.33% | 3.29% | 88.34% |
* General Sector Average
DE:SRT3
Sartorius
227.60
50.71
28.67%
DE:AFX
Carl Zeiss Meditec
30.96
-15.87
-33.88%
DE:G1A
GEA Group AG
63.80
1.84
2.97%
DE:GXI
Gerresheimer
27.32
-17.06
-38.44%
DE:PFV
Pfeiffer Vacuum Technology
165.00
16.07
10.79%
DE:SBS
STRATEC Biomedical
20.35
-5.36
-20.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.